



NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Biocon Pharma Limited Receives US FDA Approval for Daptomycin Injection ANDA

Bengaluru, Karnataka, India, August 30, 2024

"This is to inform you that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received approval of its ANDA for Daptomycin for injection (500mg vial), from the U.S. Food and Drug Administration (US FDA). This product is indicated for use in the treatment of complicated skin and skin structure infections (cSSSI). It is also used to treat Staphylococcus aureus infections in the bloodstream (bacteremia), including right-sided infective endocarditis in adult patients.

The approval further adds to Biocon's portfolio of complex drug products."